Azenta Inc Stock Price, News & Analysis

Azenta (NASDAQ: AZTA) reported its Q2 FY2025 financial results with revenue of $143 million, showing a 5% year-over-year increase and 6% organic growth. The company's Sample Management Solutions revenue grew 8% to $80 million, while Multiomics revenue increased 2% to $64 million. Despite revenue growth, Azenta reported a GAAP operating loss of $16 million with operating margin at -11.3%. The company maintained strong liquidity with $540 million in cash and equivalents. Adjusted EBITDA was $14 million with a 10% margin, showing a 400 basis point improvement year-over-year. Management reiterated its FY2025 guidance, expecting organic revenue growth of 3-5% and adjusted EBITDA margin expansion of approximately 300 basis points.

Azenta (Nasdaq: AZTA) has scheduled its fiscal 2025 second quarter earnings announcement for Wednesday, May 7, 2025, before market opening. The earnings report will cover the quarter ended March 31, 2025.

The company will host a conference call and live webcast to discuss the financial results on May 7, 2025, at 8:30 a.m. Eastern Time. Investors, analysts, and media representatives can access the live webcast through Azenta's investor relations website. A replay of the event will be available starting May 8, 2025, at 8:30 a.m. ET.

Azenta (Nasdaq: AZTA) has released its 2024 Environmental, Social, & Governance (ESG) Report, outlining achievements across three main pillars: Environmental Protection, Social Impact, and Responsible Operations.

Key 2024 milestones include:

• ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions compared to 2022
• Over 60% electricity sourced from renewable sources
• Launch of BioArc™ Ultra for eco-friendly sample storage
• Introduction of LGBTQIA+ Employee Resource Group (Azenta PRISM)
• Implementation of Azenta THRIVE platform with LinkedIn Learning® integration
• 100% of global buyer team trained on sustainable sourcing
• EcoVadis® partnership expansion to evaluate ESG performance of over 50% of Tier 1 suppliers by spend

Azenta (Nasdaq: AZTA) has announced its participation in the upcoming Virtual KeyBanc Capital Markets Healthcare Forum. The company's Executive Vice President and Chief Financial Officer, Lawrence Y. Lin, will deliver a presentation at the event on Wednesday, March 19, 2025, at 10:30 am ET.

Investors and interested parties can access the live webcast through the Azenta investor relations website at https://investors.azenta.com/events. A replay option will be made available after the presentation concludes.

Azenta (NASDAQ: AZTA) reported Q1 FY2025 results with revenue from continuing operations at $148 million, up 4% year-over-year. The company's performance was marked by growth in both major segments: Sample Management Solutions revenue reached $81 million (+3% YoY) and Multiomics revenue hit $66 million (+6% YoY).

The company reported a diluted EPS loss of ($0.21) from continuing operations and total diluted EPS of ($0.29). Adjusted EBITDA was $13 million with a margin of 9.0%, showing a 400 basis point improvement year-over-year. The quarter ended with $530 million in cash, cash equivalents, and marketable securities, generating free cash flow of $22 million.

For FY2025, Azenta maintains its guidance of 3-5% organic revenue growth and expects adjusted EBITDA margin expansion of approximately 300 basis points compared to FY2024.

Azenta (NASDAQ: AZTA) announced the election of Dipal Doshi to its Board of Directors at its Annual Meeting of Stockholders. Doshi, who currently serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in the biotechnology and pharmaceutical industries.

John Marotta, President and CEO of Azenta, highlighted Doshi's exceptional leadership qualities and valuable experience in strategy, operational and commercial growth, along with his perspective as a current public company CEO. Doshi expressed enthusiasm about joining Azenta during a important period in its development, emphasizing the company's strong market leadership position and commitment to growth and innovation.

Azenta (Nasdaq: AZTA) has announced it will release its fiscal first quarter 2025 financial results on Wednesday, February 5, 2025, before market opening. The earnings report will cover the period ended December 31, 2024.

The company will host a conference call and live webcast to discuss the results on the same day at 8:30 a.m. Eastern Time. The webcast will be accessible through Azenta's investor relations website, with a replay available starting February 6, 2025, at 8:30 a.m. ET.

Azenta (Nasdaq: AZTA) has been selected by UK Biocentre to provide its BioArc Ultra automated storage system for expanding large-scale sample storage capabilities. This addition complements seven existing BioArc Flex systems at their facility. The new system will be installed at UK Biocentre's 70,000 square-foot facility in Milton Keynes, England.

The BioArc Ultra will increase the facility's storage capacity by 16 million samples, adding to its current 35 million sample capacity. The system features high-density, fully automated -80°C storage with picking capability of up to 9 million picks per year. The solution includes FluidX 2D-coded screw-cap tubes for enhanced inventory management.

Key benefits include reduced footprint, lower labor requirements, and decreased electricity costs. The system employs an eco-friendly refrigeration system with zero Ozone Depletion Potential and zero Global Warming Potential. UK Biocentre will use this technology to support the Our Future Health study, which aims to develop new ways to prevent, detect, and treat diseases across up to 5 million people in the UK.

Azenta (Nasdaq: AZTA) has announced its participation in the Stephens Annual Investment Conference on Wednesday, November 20, 2024. The company's management will deliver a presentation starting at 1:00 pm CT. Investors and interested parties can access the live webcast through Azenta's investor relations website. A replay option will be made available after the event concludes.